ANNX
Annexon, Inc.
$5.12
-3.21%
$838.9M
No data for this timeframe.
Vol
Market Cap$838.9M
Cap SizeSmall Cap
Analyst ConsensusStrong Buy (88%)
Inst. Holders8 funds
Inst. Value$126.5M
Inst. Activity3 buys / 0 sells
Insider Activity4B / 10S
Insider Net $$3.1M
Reddit Sentiment67° Warm
SEC Reports6
Press Releases1
Recent Activity
Jun 5, 2026
short_volume
Short Volume: ANNX — 66.9% short (0.4M / 0.7M)
Short: 442,181 | Exempt: 0 | TRF Vol: 661,225 | Short Ratio: 66.9% | Off-exchange volume (dark pool
May 28, 2026
Insider
Satter Muneer A bought 613,497 shares
Director @ $5.41 ($3.3M)
May 12, 2026
SEC
Goldman Sachs initiates ANNX at Neutral — PT $7 (+23%) vs. consensus $13.71
ANALYST-UPGRADE — Impact 4/10
May 11, 2026
Insider
Carson William H. bought 8,000 shares
Director @ $5.78 ($46.2K)
Apr 16, 2026
SEC
Clear Street initiates coverage on ANNX with a Buy rating and $17 price target, implying 193% upside from the current $5
ANALYST-UPGRADE — Impact 8/10
Apr 16, 2026
SEC
Chardan Capital initiates coverage on ANNX with a Buy rating and $16 price target, implying 176% upside from the current
ANALYST-UPGRADE — Impact 7/10
Apr 10, 2026
Insider
Carson William H. bought 8,000 shares
Director @ $6.20 ($49.6K)
Inst.
VANGUARD GROUP INC — ADD
7,753,387 shares ($38.9M)
Price Targets
$13.13
+152.4% upside
Strong Buy
Current $5.20
Low $7.00
Median $11.50
High $27.00
8 analysts
$7.00
$27.00
Analyst Ratings
4Strong Buy
11Buy
2Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 12, 2026 | Goldman Sachs | INITIATE | Neutral |
| Mar 20, 2026 | Chardan Capital | MAINTAIN | Buy → Buy |
| Dec 23, 2025 | Chardan Capital | INITIATE | Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.24 ▲ +20.6% | $-0.27 — $-0.22 | 29% YoY | 6 |
| Next Q | $-0.25 ▲ +11.1% | $-0.30 — $-0.21 | 32% YoY | 6 |
| Current FY | $-0.98 ▲ +15.5% | $-1.14 — $-0.86 | 27% YoY | 6 |
| Next FY | $-0.92 ▲ +3.5% | $-1.28 — $-0.64 | 6% YoY | 6 |
Latest Reports
BULLISH
ANALYST-UPGRADE
8/10
Clear Street initiates coverage on ANNX with a Buy rating and $17 price target, implying 193% upside from the current $5
Apr 16, 2026
BULLISH
ANALYST-UPGRADE
7/10
Chardan Capital initiates coverage on ANNX with a Buy rating and $16 price target, implying 176% upside from the current
Apr 16, 2026
NEUTRAL
Press
4/10
Annexon Biosciences reported fourth quarter and full year 2025 financial results, highlighting a strong cash position of
Mar 30, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| FMR LLC | $51.3M | TRIM |
| VANGUARD GROUP INC | $38.9M | ADD |
| MORGAN STANLEY | $14.3M | DOUBLED |
| BANK OF AMERICA CORP | $8.1M | ADD |
| CHARLES SCHWAB INVESTMENT MANAGEMENT | $5.3M | ADD |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 28, 2026 | Satter Muneer | BUY | $3.3M |
| May 11, 2026 | Carson William | BUY | $46.2K |
| Apr 10, 2026 | Carson William | BUY | $49.6K |
| Mar 10, 2026 | Carson William | BUY | $45.4K |
| Mar 2, 2026 | ARTIS DEAN | SELL | $32.0K |
Reddit Sentiment
67°
Warm
Bearish
Neutral
Bullish
8 institutional holders with $126.5M total value (25,203,027 shares) as of 2025-Q4. Top holders: FMR, VANGUARD, MORGAN. Net buying activity: 3 institutions added/increased vs 0 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | FMR LLC | 10,222,470 | $51.3M | 40.6% | TRIM -29.4% |
| 2 | VANGUARD GROUP INC | 7,753,387 | $38.9M | 30.8% | ADD +32.9% |
| 3 | MORGAN STANLEY | 2,856,143 | $14.3M | 11.3% | DOUBLED +263.9% |
| 4 | BANK OF AMERICA CORP /DE/ | 1,605,581 | $8.1M | 6.4% | ADD +39.9% |
| 5 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 1,057,060 | $5.3M | 4.2% | ADD +33.8% |
| 6 | RENAISSANCE TECHNOLOGIES LLC | 802,600 | $4.0M | 3.2% | TRIM -33.1% |
| 7 | WELLS FARGO & COMPANY/MN | 573,748 | $2.9M | 2.3% | ADD +40.1% |
| 8 | TWO SIGMA INVESTMENTS, LP | 332,038 | $1.7M | 1.3% | ADD +38.8% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| VANGUARD GROUP INC | ADD | 5,835,112 | 7,753,387 | +32.9% | $38.9M | 2025-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | ADD | 790,250 | 1,057,060 | +33.8% | $5.3M | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 409,477 | 573,748 | +40.1% | $2.9M | 2025-Q4 |
| FMR LLC | TRIM | 15,695,226 | 11,081,163 | -29.4% | $33.8M | 2025-Q3 |
| MORGAN STANLEY | DOUBLED | 832,540 | 3,029,848 | +263.9% | $9.2M | 2025-Q3 |
| TWO SIGMA INVESTMENTS, LP | ADD | 201,160 | 279,134 | +38.8% | $851.4K | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | ADD | 1,038,724 | 1,452,795 | +39.9% | $3.5M | 2025-Q2 |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 1,162,437 | 777,900 | -33.1% | $1.9M | 2025-Q2 |
| TWO SIGMA INVESTMENTS, LP | NEW | — | 201,160 | — | $482.8K | 2025-Q2 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 493,700 | 1,162,437 | +135.5% | $2.2M | 2025-Q1 |
| WELLS FARGO & COMPANY/MN | ADD | 235,755 | 347,892 | +47.6% | $671.4K | 2025-Q1 |
| CITADEL ADVISORS LLC | TRIM | 128,998 | 79,255 | -38.6% | $153.0K | 2025-Q1 |
| TWO SIGMA INVESTMENTS, LP | EXIT | 137,183 | 0 | -100.0% | $0.00 | 2025-Q1 |
| MORGAN STANLEY | TRIM | 1,235,485 | 644,677 | -47.8% | $3.3M | 2024-Q4 |
| UBS Group AG | ADD | 219,127 | 328,721 | +50.0% | $1.7M | 2024-Q4 |
| CITADEL ADVISORS LLC | ADD | 92,338 | 128,998 | +39.7% | $661.8K | 2024-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 732,216 | — | $4.3M | 2024-Q3 |
8 unique insiders with 14 transactions. Net insider value: $3.1M ($3.5M bought, $313.4K sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 28, 2026 | Satter Muneer A | Director | BUY | 613,497 | $5.41 | $3.3M |
| May 11, 2026 | Carson William H. | Director | BUY | 8,000 | $5.78 | $46.2K |
| Apr 10, 2026 | Carson William H. | Director | BUY | 8,000 | $6.20 | $49.6K |
| Mar 10, 2026 | Carson William H. | Director | BUY | 8,000 | $5.67 | $45.4K |
| Mar 2, 2026 | ARTIS DEAN RICHARD | EVP & CHIEF SCIENTIFIC OFFICER | SELL | 5,894 | $5.43 | $32.0K |
| Mar 2, 2026 | Dananberg Jamie | CHIEF MEDICAL OFFICER | SELL | 5,820 | $5.43 | $31.6K |
| Mar 2, 2026 | Lew Jennifer | EVP & CHIEF FINANCIAL OFFICER | SELL | 5,565 | $5.42 | $30.2K |
| Mar 2, 2026 | Overdorf Michael | EVP & CHIEF BUSINESS OFFICER | SELL | 4,339 | $5.42 | $23.5K |
| Mar 2, 2026 | Yednock Ted | EVP & CHIEF INNOVATION OFFICER | SELL | 5,566 | $5.42 | $30.2K |
| Feb 19, 2026 | Yednock Ted | EVP & CHIEF INNOVATION OFFICER | A | 62,500 | $0.00 | $0.00 |
| Feb 19, 2026 | Yednock Ted | EVP & CHIEF INNOVATION OFFICER | A | 250,000 | $0.00 | $0.00 |
| Feb 19, 2026 | Love Douglas | PRESIDENT AND CEO | A | 1,250,000 | $0.00 | $0.00 |
| Feb 19, 2026 | Dananberg Jamie | CHIEF MEDICAL OFFICER | A | 56,250 | $0.00 | $0.00 |
| Feb 19, 2026 | Dananberg Jamie | CHIEF MEDICAL OFFICER | A | 225,000 | $0.00 | $0.00 |
| Feb 19, 2026 | Overdorf Michael | EVP & CHIEF BUSINESS OFFICER | A | 62,500 | $0.00 | $0.00 |
| Feb 19, 2026 | Overdorf Michael | EVP & CHIEF BUSINESS OFFICER | A | 250,000 | $0.00 | $0.00 |
| Feb 19, 2026 | ARTIS DEAN RICHARD | EVP & CHIEF SCIENTIFIC OFFICER | A | 62,500 | $0.00 | $0.00 |
| Feb 19, 2026 | ARTIS DEAN RICHARD | EVP & CHIEF SCIENTIFIC OFFICER | A | 250,000 | $0.00 | $0.00 |
| Feb 19, 2026 | Lew Jennifer | EVP & CHIEF FINANCIAL OFFICER | A | 62,500 | $0.00 | $0.00 |
| Feb 19, 2026 | Lew Jennifer | EVP & CHIEF FINANCIAL OFFICER | A | 250,000 | $0.00 | $0.00 |
| Feb 18, 2026 | Lew Jennifer | EVP & CHIEF FINANCIAL OFFICER | SELL | 7,851 | $5.11 | $40.1K |
| Feb 18, 2026 | Dananberg Jamie | CHIEF MEDICAL OFFICER | SELL | 5,290 | $5.10 | $27.0K |
| Feb 18, 2026 | Yednock Ted | EVP & CHIEF INNOVATION OFFICER | SELL | 7,857 | $5.11 | $40.1K |
| Feb 18, 2026 | Overdorf Michael | EVP & CHIEF BUSINESS OFFICER | SELL | 6,225 | $5.10 | $31.7K |
| Feb 18, 2026 | ARTIS DEAN RICHARD | EVP & CHIEF SCIENTIFIC OFFICER | SELL | 5,290 | $5.10 | $27.0K |
6 SEC filing reports analyzed. Sentiment: 4 bullish, 1 bearish, 0 mixed, 1 neutral. Avg impact: 5.2/10.
BULLISH
ANALYST-UPGRADE
7/10
Chardan Capital initiates coverage on ANNX with a Buy rating and $16 price target, implying 176% ups
Apr 16, 2026
BULLISH
ANALYST-UPGRADE
8/10
Clear Street initiates coverage on ANNX with a Buy rating and $17 price target, implying 193% upside
Apr 16, 2026
BEARISH
ANALYST-UPGRADE
4/10
Goldman Sachs initiates ANNX at Neutral — PT $7 (+23%) vs. consensus $13.71
May 12, 2026
BULLISH
ANALYST-UPGRADE
3/10
Chardan Capital initiates ANNX at Buy — PT $16 (+198%) as cluster of bullish coverage builds
May 16, 2026
BULLISH
PRESS-RELEASE
6/10
Annexon reported Q1 2026 EPS of -$0.23, beating consensus of -$0.30 by 23%, with net loss narrowing
May 7, 2026
NEUTRAL
CLUSTER
3/10
Five executive officers at Annexon, Inc. (ANNX) sold shares in a coordinated open-market transaction
Mar 4, 2026
Current analyst consensus: Strong Buy (88% buy). Based on 17 analysts: 4 strong buy, 11 buy, 2 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$13.13 mean target
+152.4% upside
Strong Buy (1.40)
$7.00 Low
$27.00 High
| Metric | Value |
|---|---|
| Current Price | $5.20 |
| Target Low | $7.00 |
| Target Mean | $13.13 |
| Target Median | $11.50 |
| Target High | $27.00 |
| # Analysts | 8 |
| Recommendation | Strong Buy (1.40) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.24 | $-0.27 | $-0.22 | 29.5% | +20.6% | 4↑ 0↓ | $0.0B | 0.0% | 6 |
| Next Q 2026-09-30 |
$-0.25 | $-0.30 | $-0.21 | 31.9% | +11.1% | 4↑ 0↓ | $0.0B | 0.0% | 6 |
| Current FY 2026-12-31 |
$-0.98 | $-1.14 | $-0.86 | 26.7% | +15.5% | 4↑ 0↓ | $0.0B | 0.0% | 6 |
| Next FY 2027-12-31 |
$-0.92 | $-1.28 | $-0.64 | 6.0% | +3.5% | 3↑ 1↓ | $0.0B | 0.0% | 6 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.240 | |
| 7d ago | $-0.237 | -0.002 |
| 30d ago | $-0.302 | +0.062 |
| 60d ago | $-0.337 | +0.097 |
| 90d ago | $-0.337 | +0.097 |
2 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 2 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 12, 2026 | Goldman Sachs | INITIATE | — | Neutral |
| Mar 20, 2026 | Chardan Capital | MAINTAIN | Buy | Buy |
| Dec 23, 2025 | Chardan Capital | INITIATE | — | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 4 | 11 | 2 | 0 | 0 | 88% | |
| May 1, 2026 | 4 | 11 | 1 | 0 | 0 | 94% | |
| Apr 1, 2026 | 4 | 11 | 1 | 0 | 0 | 94% | |
| Mar 1, 2026 | 4 | 11 | 1 | 0 | 0 | 94% | |
| Feb 1, 2026 | 4 | 11 | 1 | 0 | 0 | 94% | |
| Jan 1, 2026 | 4 | 11 | 1 | 0 | 0 | 94% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
67°
Warm
Bearish
Neutral
Bullish
2 mentions
2 bullish
0 bearish
2 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Apr 25, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Apr 25, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
Recent Reddit Threads
Jun 5, 2026
short_volume
Short Volume: ANNX — 66.9% short (0.4M / 0.7M)
Short: 442,181 | Exempt: 0 | TRF Vol: 661,225 | Short Ratio: 66.9% | Off-exchange volume (dark pool + OTC)
Jun 2, 2026
short_volume
Short Volume: ANNX — 57.4% short (0.5M / 0.8M)
Short: 475,414 | Exempt: 52 | TRF Vol: 827,886 | Short Ratio: 57.4% | Off-exchange volume (dark pool + OTC)
May 29, 2026
short_volume
Short Volume: ANNX — 56.8% short (0.4M / 0.7M)
Short: 411,892 | Exempt: 0 | TRF Vol: 725,184 | Short Ratio: 56.8% | Off-exchange volume (dark pool + OTC)
May 26, 2026
short_volume
Short Volume: ANNX — 94.0% short (3.3M / 3.5M)
Short: 3,326,317 | Exempt: 0 | TRF Vol: 3,539,125 | Short Ratio: 94.0% | Off-exchange volume (dark pool + OTC)
May 18, 2026
other
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
<p align="justify">BRISBANE, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next g
May 18, 2026
earnings_calendar
ANNX Q1 2026 Earnings Scheduled — 2026-05-18
May 18, 2026
short_volume
Short Volume: ANNX — 77.6% short (1.0M / 1.3M)
Short: 1,012,793 | Exempt: 9 | TRF Vol: 1,304,950 | Short Ratio: 77.6% | Off-exchange volume (dark pool + OTC)
May 15, 2026
short_volume
Short Volume: ANNX — 73.6% short (0.4M / 0.5M)
Short: 395,249 | Exempt: 15 | TRF Vol: 537,142 | Short Ratio: 73.6% | Off-exchange volume (dark pool + OTC)
May 13, 2026
short_volume
Short Volume: ANNX — 59.0% short (0.3M / 0.6M)
Short: 343,018 | Exempt: 0 | TRF Vol: 581,057 | Short Ratio: 59.0% | Off-exchange volume (dark pool + OTC)
May 11, 2026
earnings_calendar
ANNX Q1 2026 Earnings Scheduled — 2026-05-11
May 7, 2026
earnings
Annexon Reports First Quarter 2026 Financial Results, Portfolio Progress and Key Anticipated Milestones
<p align="center"><em>Topline Pivotal Phase 3 Data for Vonaprument for the Treatment of Geographic Atrophy (GA) Expected Q4 2026, with Potential to Re
May 7, 2026
short_volume
Short Volume: ANNX — 56.2% short (0.4M / 0.7M)
Short: 408,824 | Exempt: 4,000 | TRF Vol: 726,869 | Short Ratio: 56.2% | Off-exchange volume (dark pool + OTC)
May 6, 2026
other
Annexon to Present at the Bank of America Securities Health Care Conference 2026
<p>BRISBANE, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platfo
Apr 30, 2026
short_volume
Short Volume: ANNX — 59.2% short (0.4M / 0.6M)
Short: 364,081 | Exempt: 0 | TRF Vol: 614,744 | Short Ratio: 59.2% | Off-exchange volume (dark pool + OTC)
Apr 29, 2026
short_volume
Short Volume: ANNX — 60.2% short (0.6M / 0.9M)
Short: 551,356 | Exempt: 0 | TRF Vol: 916,631 | Short Ratio: 60.2% | Off-exchange volume (dark pool + OTC)